- Haleon
- 31 July 2025 09:17:13
Source: Sharecast
Haleon said adjusted operating profits had risen 9.9% to £1.24bn, while organic revenues grew 3.2% to £5.48bn, with its EMEA & Latin America and Asia-Pacific units offsetting a slight decline in its North American operations.
The FTSE 100-listed group stated its oral health division led category growth, up 7.6% on an organic basis, supported by innovations in Sensodyne and Parodontax. Pain relief revenues rose 2.5%, while vitamins, minerals & supplements edged up 0.9%. Respiratory and digestive health declined slightly.
Gross profit margins expanded by 160bps organically, aided by supply chain efficiencies and pricing, while adjusted diluted earnings per share rose 2.2% to 9.2p. Free cash flow jumped £184m to £734m, excluding proceeds from its divestment of ChapStick. Haleon also declared an interim dividend of 2.2p per share, up 10% year-on-year.
As a result, Haleon upgraded its guidance to "high-single digit organic operating profit growth" for FY25 but warned that organic revenues would now only grow around 3.5%, down from a prior range of 4–6%, citing sluggish performance in its North American respiratory portfolio.
CEO Brian McNamara said: "We expect an improving trend for organic revenue growth in the second half, with innovations supporting a positive performance in EMEA & LatAm and Asia Pacific. The consumer environment in North America is likely to remain subdued.
"We remain encouraged by the opportunities for growth across the business and [are] confident in delivering our medium-term guidance."
As of 0915 BST, Haleon shares were down 2.0% at 357.60p.
Reporting by Iain Gilbert at Sharecast.com
